BOSTON and ROLLE, Switzerland - SOPHiA GENETICS (NASDAQ:SOPH), in collaboration with the French Kidney Cancer Research Network (UroCCR), has announced a significant advancement in the predictive analysis of post-operative outcomes for renal cell carcinoma (RCC) patients.
The study, recently published in npj Precision Oncology, utilized a multimodal algorithm that demonstrated superior prediction capabilities compared to existing prognostic scores.
This research is a continuation of a partnership that began in 2021, aiming to integrate artificial intelligence (AI) in the prognosis of kidney cancer progression post-surgery.
The UroCCR database, which is one of the largest of its kind, provided a diverse range of real-world data from over 3,300 patients in France treated between May 2000 and January 2020. SOPHiA GENETICS applied its proprietary AI technology to this multimodal data, resulting in accurate predictions that outperformed most common risk scores.
Thierry Colin, VP of Multimodal Research and Development at SOPHiA GENETICS, emphasized the growing complexity of health data and how AI can enhance personalized diagnostics and treatment. The AI model developed through this collaboration could potentially aid in clinical decision-making, indicating which patients might require adjuvant systemic therapy and which could be monitored through surveillance alone.
Pr Jean-Christophe Bernhard, head of UroCCR and Urologic Surgeon at CHU Bordeaux, highlighted the shared database's role in promoting precision medicine for kidney cancer patients. The study's results have shown the effectiveness of AI in analyzing real-world data, and SOPHiA GENETICS' technology and network have been instrumental in this research.
SOPHiA GENETICS, a cloud-native software company, aims to standardize data-driven medicine through its SOPHiA DDM™ Platform. This platform allows for the integration and analysis of multimodal data, facilitating the development of predictive models for research inquiries.
The collaboration between SOPHiA GENETICS and UroCCR exemplifies the potential of AI in improving patient care and advancing medical research. The findings from the study are based on a press release statement and signify a step forward in the application of AI in oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.